The KLF13 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population, derived from the human A-549 lung adenocarcinoma epithelial cell line. This loss-of-function model targets the Kr??ppel-like factor 13 (KLF13) gene, a transcription factor involved in key cellular processes including proliferation, differentiation, and apoptosis. The polyclonal format provides a heterogeneous pool of edited cells, enabling functional studies in a population context without implying monoclonality or complete biallelic knockout. Supplied as a ready-to-use population, it is suitable for immediate experimental deployment.
A-549 cells are a well-established model of human non-small cell lung cancer, originally isolated from a lung adenocarcinoma. These epithelial cells retain characteristic features of the tumor microenvironment and are extensively employed in cancer biology research, including investigations of oncogenic signaling, drug response, and metastasis. Their robust growth characteristics and well-characterized genomic background make them an ideal host for targeted gene disruption, allowing direct interrogation of KLF13 function in a relevant disease setting.
KLF13 encodes a Kr??ppel-type zinc finger transcription factor that operates downstream of transforming growth factor-beta (TGF-??) signaling. It is activated by TGF-??1 and hypoxia-inducible factor 1-alpha (HIF1A), and its transcriptional activity is modulated through interactions with SP1, SMAD3, histone deacetylase 1 (HDAC1), and the coactivator CBP/p300. KLF13 directly regulates target genes such as CDKN1A (p21), BAX, BCL2, CCND1, and COL1A1, thereby controlling cell cycle progression and apoptotic responses. In the canonical TGF-?? pathway, ligand engagement of TGF-?? receptors (TGFBR) leads to phosphorylation of SMAD2/3, which partner with SMAD4 to translocate into the nucleus, where KLF13 cooperates with SMAD complexes to fine-tune gene expression. Additionally, KLF13 intersects with the MAPK/ERK cascade, linking extracellular growth signals to transcriptional outputs.
Disruption of KLF13 in the A-549 lung adenocarcinoma background is anticipated to perturb cellular responses to TGF-?? stimulation, potentially affecting proliferation, apoptosis, and sensitivity to stress signals. Since TGF-?? signaling exhibits dual roles in cancer??acting as a tumor suppressor in early stages and promoting invasion in advanced disease??KLF13 knockout may unveil context-dependent functions. This model therefore offers a valuable tool for dissecting the contribution of KLF13 to lung cancer progression and for evaluating its therapeutic potential.
This polyclonal knockout cell population is well-suited for diverse research applications, including gene function analysis, cancer cell biology studies, and drug target validation. Typical experimental approaches include Western blotting and RT-qPCR for confirming KLF13 depletion and assessing downstream targets, RNA-seq for transcriptomic profiling, MTT or BrdU-based proliferation assays, Annexin V/PI apoptosis detection, flow cytometric cell cycle analysis, and migration/invasion assays. Furthermore, KLF13 reporter gene assays and phospho-SMAD2 western blotting enable detailed dissection of TGF-?? signaling dynamics. For technical inquiries or customized options, please contact Ascent Research.
